Drug

Ziprasidone

In clinical development

Emerging researchLate-stage development

Also known as Geodon, Ziprasidona, Ziprasidone Hydrochloride, Ziprasidone Mesylate+1 more

Geodon, Ziprasidona, Ziprasidone Hydrochloride, Ziprasidone Mesylate, Ziprasidonum.

RxNorm115698 ChEMBLCHEMBL708 ATCN05AE04UNII6UKA5VEJ6X

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia

Clinical trial2026-07-08Results expected Q1 2027 · ClinicalTrials.gov

Effectiveness of Switching Antipsychotic Medications

Clinical trial2026-05-15Results posted · ClinicalTrials.gov

A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder

Clinical trial2025-04-08Results posted · ClinicalTrials.gov

A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Iloperidone in Schizophrenic Patients in Acute Exacerbation Followed by a Long-term Treatment Phase.

Clinical trial2024-12-13Results posted · ClinicalTrials.gov

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-group Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

Clinical trial2024-11-12Results posted · ClinicalTrials.gov

Ziprasidone vs Placebo in the Prevention of Psychosis Among Symptomatic Adolescents and Young Adults at Prodromal Risk

Clinical trial2023-03-27Results posted · ClinicalTrials.gov

Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building

Clinical trial2022-12-31Primary completion · ClinicalTrials.gov

A Sixteen-Week, Multi-Center, Open-Label Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone In Subjects Diagnosed With Schizophrenia Or Schizoaffective Disorder

Clinical trial2021-03-29Results posted · ClinicalTrials.gov

A Three-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Add-On Oral Ziprasidone in Subjects With Acute Mania Treated With Lithium or Divalproex

Clinical trial2021-03-29Results posted · ClinicalTrials.gov

26-Week Open-Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)

Clinical trial2021-03-25Results posted · ClinicalTrials.gov

A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder.

Research2012-12-01The Journal of clinical psychiatry

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Research2005-09-19The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Ziprasidone

Aliases & brands

GeodonZiprasidonaZiprasidone HydrochlorideZiprasidone MesylateZiprasidonum

RxNorm CUI

115698

ChEMBL ID

CHEMBL708

ATC codes

N05AE04

UNII

6UKA5VEJ6X

Clinical trials

96 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2020

Active studies

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 96

Early Phase 11Phase 15Phase 1 / 21Phase 212Phase 2 / 32Phase 326Phase 443Phase N / A6

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building

Unknown statusPH IVShanghai Mental Health Centern=3502022

A Multi-Center,Open-Labeled,Intervention Study:The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation

Unknown statusPH IVKey trialYang Fuden=1,0002017

Effect of Atypical Antipsychotics on Gene Expression in Soft Tissues of Healthy Subjects - A Placebo Controlled Randomised Pilot Study

CompletedPH IVMedical University of Viennan=162017

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics for the Prevention of Relapse in Long-term Stabilized Schizophrenic Patients: a Randomized, Single-blind, Longitudinal Trial

CompletedPH IVTechnical University of Munichn=212016

Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase

Unknown statusPH IVGuiyun Xun=1202015

Recent completions

Trials that read out recently, adding to the completed evidence base.

Reducing the Abuse Liability of Prescription Opioids

CompletedPH IThe University of Texas Health Science Center at San Antonion=152020

CompletedPH IIAstellas Pharma Global Development, Inc.n=2332019

MIND-USA Study: Modifying the Impact of ICU-Associated Neurological Dysfunction

CompletedPH IIIVanderbilt University Medical Centern=5662018

Effect of Atypical Antipsychotics on Gene Expression in Soft Tissues of Healthy Subjects - A Placebo Controlled Randomised Pilot Study

CompletedPH IVMedical University of Viennan=162017

CompletedPH IVTechnical University of Munichn=212016

Phase IV Study of Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II): a 3-year Follow-up

CompletedPH IVFundación Marques de Valdecillan=2032015

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20052012

Most influential

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

The New England journal of medicine · 2005 · 3,569 cites

A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder.

The Journal of clinical psychiatry · 2012 · 15 cites

Related drugs

4 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Olanzapine

Studied across 3 of the same disease areas as Ziprasidone in the shared literature.

3 shared diseases1 shared paper

Perphenazine

Studied across 3 of the same disease areas as Ziprasidone in the shared literature.

3 shared diseases1 shared paper

Quetiapine Fumarate

Studied across 3 of the same disease areas as Ziprasidone in the shared literature.

3 shared diseases1 shared paper

Risperidone

Studied across 3 of the same disease areas as Ziprasidone in the shared literature.

3 shared diseases1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials